 |
Jerusalem, Israel, December 18, 2006
Teva Announces Launch Of Generic Wellbutrin Xl® Tablets, 300 Mg Under Agreement With Anchen And IMPAX
|
|
Jerusalem, Israel, November 29, 2006
Teva Announces Tentative Approval Of Sumatriptan Succinate Tablets
|
|
Jerusalem, Israel, November 21, 2006
Teva Announces Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
|
|
Jerusalem, Israel, November 14, 2006
Court of Appeals Affirms Teva's Generic Zocor® Exclusivity
|
|
Jerusalem, Israel, November 7, 2006
Teva Reports Third Quarter 2006 Results
|
|
jerusalem, Israel, November 7, 2006
Teva Announces $600 Million Securities Repurchase Program
|
|
Jerusalem, Israel,, October 31, 2006
Teva announces Global In-Market Third Quarter Sales of Copaxone® Increased 15% To $354 Million
|
|
Jerusalem, Israel, October 26, 2006
Teva to Report Third Quarter 2006 Financial Results on
|
|
Jerusalem, Israel, October 18, 2006
Teva Announces Planned Retirement of President & CEO in 2007
|
|
Jerusalem, Israel, October 16, 2006
Teva Announces Oxycontin® Litigation Dismissed; Settlement With Purdue Finalized
|
|
Jerusalem, Israel, October 12, 2006
Teva Announces Tentative Approval for Generic Risperdal® Oral Solution
|
|
Jerusalem, Israel, September 28, 2006
New Data Confirmed Antibodies to Copaxone® Do Not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
|
|
Jerusalem and Carmiel, Israel, September 26, 2006
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. announce a Collaboration Agreement for the development of two Biopharmaceuticals, based on Protalix's recombinant plant cell expression technology
|
|
Jerusalem and Ashdod, Israel, September 21, 2006
Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals
|
|
Jerusalem, Israel and Lund, Sweden, September 5, 2006
Laquinimod Phase IIb Trial confirms efficacy and favorable safety profile and shows significant reduction in the rate of inflammatory disease activity
|
|
Jerusalem, Israel, August 29, 2006
Teva Announces Settlement Of Oxycontin® Litigation
|
|
Jerusalem, Israel, August 23, 2006
Teva Announces Further Steps in Global Rationalization Strategy
|
|
Jerusalem, Israel, August 21, 2006
Teva Announces Health Canada Approves Azilect® (Rasagiline) for Parkinson's Disease
|
|
Jerusalem, Israel, August 14, 2006
Teva Announces Launch of Generic Zoloft®
|
|
Jerusalem, Israel, August 8, 2006
Teva Reports Second Quarter 2006 Results
|
|
Jerusalem, Israel, August 4, 2006
Teva Announces Final Approval of Venlafaxine HCL Tablets
|
|
Jerusalem, Israel, August 2, 2006
Teva Announces Global In-Market Second Quarter Sales of Copaxone® Increased 22% to $353 Million
|
|
Jerusalem, Israel, July 27, 2006
Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-Remitting Multiple Sclerosis
|
|
Jerusalem, Israel, July 26, 2006
Teva to Report Second Quarter 2006 Financial Results on August 8, 2006
|
|
Jerusalem, Israel, July 20, 2006
Teva Announces Final Approval of Meloxicam Tablets
|
|
Jerusalem, Israel,, July 12, 2006
Teva Announces Tentative Approval of Generic Lotrel®
|
|
Jerusalem, Israel, July 12, 2006
Teva Will Be Sole Promoter of Azilect® for Parkinson's Disease in the United States
|
|
Jerusalem, Israel, June 30, 2006
Teva Receives FDA Approval for Generic Zoloft® Tablets
|
|
Jerusalem, Israel, June 27, 2006
Teva Provides Generic Biaxin® Xl Update
|
|
Jerusalem, Israel, June 25, 2006
Teva Receives First U.S. Approval of Generic Zocor® Tablets; Product to be Shipped Immediately
|
|
Jerusalem, Israel, June 25, 2006
Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor®
|
|
Jerusalem, Israel, June 22, 2006
Court of Appeals Rules in Favor of Teva on Biaxin® XL Preliminary Injunction
|
|
Jerusalem, Israel, June 19, 2006
Teva Receives First FDA Approval for Generic Proscar® Tablets
|
|
Jerusalem, Israel,, June 14, 2006
Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
|
|
Jerusalem, Israel, May 28, 2006
Teva Announces Tentative Approval for Generic Cozaar® Tablets
|
|
Jerusalem, Israel, May 25, 2006
Teva Announces Tentative Approval of Simvastatin Tablets; Provides Update on 180-Day Exclusivity
|
|
Jerusalem, Israel, May 22, 2006
Teva Announces Approval of Generic Lexapro® Tablets
|
|
Jerusalem, Israel, May 17, 2006
Teva Announces FDA Grants Approval of Azilect® (Rasagiline) for Parkinson's Disease
|
|
Jerusalem, Israel, May 10, 2006
Teva Reports First Quarter 2006 Results
|
|
Jerusalem, Israel, May 7, 2006
Teva Announces Approval of Polyethylene Glycol 3350 NF for Oral Solution
|
|
Jerusalem, Israel, May 5, 2006
Teva Announces Global In-Market First Quarter Sales of its Blockbuster Copaxone® Increased 29% to $329 Million
|
|
Jerusalem, Israel, April 28, 2006
Teva Recommends Rejection of "Mini-Tender" Offer from TRC Capital
|
|
Jerusalem, Israel, April 26, 2006
Teva to Report First Quarter 2006 Financial Results on May 10, 2006
|
|
Jerusalem, Israel, April 25, 2006
Teva Receives First FDA Approval for Generic Pravachol®; Appellate Court Denies Apotex Request for Injunctive Relief
|
|
Jerusalem, Israel, April 23, 2006
Teva Receives Tentative Approval for Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg
|
|
Jerusalem, Israel, April 23, 2006
Teva Provides Update on Generic Pravachol®
|
|
Jerusalem, Israel, April 20, 2006
Teva Announces Stay of Approval for Generic Pravachol Lifted
|
|
Jerusalem, Israel, April 19, 2006
District Court Denies Apotex's Request to Block Teva's Introduction of First Generic Pravachol® in the U.S.; Court Grants Stay of FDA Approval until After Close of Business Friday
|
|
Jerusalem, Israel, April 12, 2006
Teva Announces Approval of Mitoxantrone Hydrochloride Injection USP
|
|
Jerusalem, Israel, April 12, 2006
Teva Announces FDA Determination that Generic Pravachol Exclusivity Has Not Been Triggered
|
|
Jerusalem, Israel, April 6, 2006
Teva Announces that Higher Dose of Copaxone® Showed Increased Efficacy in Multiple Sclerosis (Ms)
|
|
Jerusalem, Israel, April 2, 2006
Teva Announces Approval of Deferoxamine Mesylate for Injection Usp
|
|
Jerusalem, Israel, March 30, 2006
Teva Expands Presence in China; Increases Equity Stake in Hualida Biotechnology to 60%
|
|
Jerusalem, Israel, March 16, 2006
Teva Provides Update on Generic Pravachol Exclusivity
|
|
Jerusalem, Israel, March 6, 2006
Teva Announces Tentative Approval of Topiramate Tablets, 50 Mg
|
|
Jerusalem, Israel, February 28, 2006
Teva Reports Record Sales and Net Income for the Fourth Quarter and Full Year 2005
|
|
Jerusalem, Israel, February 26, 2006
Teva Announces Tentative Approval of Ondansetron Injection USP
|
|
Jerusalem, Israel, February 24, 2006
Teva Announces Exercise of Over-Allotment Option for Convertible Debentures
|
|
Jerusalem, Israel, February 16, 2006
Teva Announces Tentative Approval of Rabeprazole Sodium Delayed-Release Tablets
|
|
Jerusalem, Israel, February 13, 2006
Teva Announces Tentative Approval of Adenosine Injection
|
|
Jerusalem, Israel, February 9, 2006
Teva Comments on Pfizer Press Release Regarding Azithromycin
|
|
Jerusalem, Israel, February 8, 2006
Teva To Report 2005 Financial Results on February 28, 2006
|
|
Jerusalem, Israel, February 1, 2006
Teva Announces Final Results of Merger Consideration in Connection With Ivax Acquisition
|
|
Jerusalem, Israel, January 30, 2006
Teva Announces Global In-Market Fourth Quarter Sales of Its Blockbuster Copaxone® Increased 24% to $323 Million
|
|
Jerusalem, Israel, January 29, 2006
Teva Announces Approval of Desmopressin Acetate Tablets
|
|
Jerusalem, Israel, January 27, 2006
Teva Announces Pricing of $1.25 Billion of Convertible Debentures
|
|
Jerusalem, Israel, January 27, 2006
Teva Announces Pricing of $1.5 Billion of Senior Notes
|
|
Jerusalem, Israel, January 27, 2006
Teva Announces Favorable Court Decision Regarding Generic Allegra. District Court Denies Motion for Preliminary Injunction
|
|
Jerusalem, Israel, January 26, 2006
Teva Completes Acquisition of Ivax
|
|
Jerusalem, Israel, January 25, 2006
Teva Announces Offering of $2.75 Billion of Senior Notes and Convertible Debentures
|
|
Jerusalem, Israel and Miami, Florida, January 23, 2006
U.S. Federal Trade Commission Clears Teva/IVAX Merger; Closing Scheduled for January 26, 2006
|
|
Jerusalem, Israel, January 12, 2006
Teva Announces Tentative Approval of Divalproex Sodium Delayed-Release Tablets
|
|
Jerusalem, Israel and Miami, Florida, January 10, 2006
Teva and IVAX Announce that FTC Review Process Continues on Track and Merger Closing is Expected Shortly
|
|
Jerusalem, Israel and Miami, Florida, January 3, 2006
Teva and IVAX Decline "Public Acquirer Fundamental Change" Option for IVAX' 1.5% Convertible Senior Notes due 2025
|
|
Jerusalem, Israel, January 1, 2006
Teva Announces Tentative Approval of Simvastatin Tablets
|
